HRMY in the 13F filings
Harmony Biosciences HLDGS In · CUSIP 413197104
- Quarter end
- 30 Sep 2023
- the date the book describes
- Filed
- 14 Nov 2023
- latest of these filings; the earliest 13 Nov 2023
- Managers listing it
- 5
- at least, of 95 tracked, among listed positions
- Comparable managers
- 93
- filed both Q2 2023 and Q3 2023; 5 listed it in both
- Shares listed
- 863,161
- combined, among listed positions
- Reported value
- $28m
- combined, at the quarter end
Managers listing HRMY in Q3 2023
5 of 5 holders
| Action | Filing | |||||
|---|---|---|---|---|---|---|
| Two Sigma Advisers LP | 292,100 | $9.6m | under 0.1% | Trimmed | -110,700 | 14 Nov 2023 (the filing on sec.gov) |
| Voloridge Investment Management LLC | 269,167 | $8.8m | under 0.1% | Added | +19,045 | 14 Nov 2023 (the filing on sec.gov) |
| Woodline Partners LP | 233,859 | $7.7m | 0.09% | Trimmed | -6,357 | 14 Nov 2023 (the filing on sec.gov) |
| PDT Partners LLC | 55,937 | $1.8m | 0.23% | Trimmed | -40,697 | 14 Nov 2023 (the filing on sec.gov) |
| Winton Group Ltd | 12,098 | $396k | under 0.1% | Trimmed | -695 | 13 Nov 2023 (the filing on sec.gov) |
Largest increases and reductions, by shares
Increases
- Voloridge Investment Management LLCexisting position · 269,167 shares now+19,045
Reductions
- Two Sigma Advisers LPexisting position · 292,100 shares now-110,700
- PDT Partners LLCexisting position · 55,937 shares now-40,697
- Woodline Partners LPexisting position · 233,859 shares now-6,357
- Winton Group Ltdexisting position · 12,098 shares now-695
New positions and exits
New (0)
No new position among listed positions.
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q4 2020 | 1 | $3.9m | n.a. | n.a. |
| Q4 2021 | 1 | $66m | n.a. | n.a. |
| Q1 2022 | 2 | $87m | n.a. | n.a. |
| Q2 2022 | 3 | $92m | n.a. | n.a. |
| Q3 2022 | 3 | $93m | n.a. | n.a. |
| Q4 2022 | 5 | $110m | n.a. | n.a. |
| Q1 2023 | 3 | $16m | n.a. | n.a. |
| Q2 2023 | 5 | $35m | n.a. | n.a. |
| Q3 2023 | 5 | $28m | n.a. | n.a. |
| Q4 2023 | 4 | $23m | 3 | 1 |
| Q1 2024 | 2 | $15m | 0 | 2 |
| Q2 2024 | 1 | $2.6m | 0 | 0 |
| Q3 2024 | 2 | $3.4m | 1 | 1 |
| Q4 2024 | 3 | $35m | 2 | 2 |
| Q1 2025 | 3 | $36m | 1 | 2 |
| Q2 2025 | 1 | $38m | 1 | 0 |
| Q3 2025 | 4 | $7.5m | 3 | 0 |
| Q4 2025 | 5 | $111m | 17 | 13 |
| Q1 2026 | 5 | $41m | 21 | 9 |
| Q2 2026 | 3 | $54m | 14 | 18 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
HRMY and LLY →HRMY and JNJ →HRMY and VRTX →Choose a stock to compare with HRMY →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own HRMY, latest filings →Back to the 13F Explorer →